Guidelines on the management of ascites in cirrhosis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Fleming, 2010, The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study, Aliment Pharmacol Ther, 32, 1343, 10.1111/j.1365-2036.2010.04473.x
Morali, 1992, Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites?, J Hepatol, 16, 249, 10.1016/S0168-8278(05)80128-X
Casado, 1998, Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings, Gastroenterology, 114, 1296, 10.1016/S0016-5085(98)70436-6
Iwakiri, 2014, Pathophysiology of portal hypertension, Clin Liver Dis, 18, 281, 10.1016/j.cld.2013.12.001
Abraldes, 2006, Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state, Am J Physiol Gastrointest Liver Physiol, 290, G980, 10.1152/ajpgi.00336.2005
Iwakiri, 2006, The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule, Hepatology, 43, S121, 10.1002/hep.20993
Schrier, 1988, Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis, Hepatology, 8, 1151, 10.1002/hep.1840080532
Cárdenas, 2003, Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites, Best Pract Res Clin Endocrinol Metab, 17, 607, 10.1016/S1521-690X(03)00052-6
Bernardi, 2015, Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis, J Hepatol, 63, 1272, 10.1016/j.jhep.2015.07.004
Subramanian V , Aithal G . The gastrointestinal system. In: In Chamberlain’s symptoms and signs in clinical medicine. 13th edn, 2010.
Cattau, 1982, The accuracy of the physical examination in the diagnosis of suspected ascites, JAMA, 247, 1164, 10.1001/jama.1982.03320330060027
Runyon, 1992, The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites, Ann Intern Med, 117, 215, 10.7326/0003-4819-117-3-215
Rector, 1984, Superiority of the serum-ascites albumin difference over the ascites total protein concentration in separation of "transudative" and "exudative" ascites, Am J Med, 77, 83, 10.1016/0002-9343(84)90440-6
Gupta, 1995, Diagnosing ascites: value of ascitic fluid total protein, albumin, cholesterol, their ratios, serum-ascites albumin and cholesterol gradient, J Gastroenterol Hepatol, 10, 295, 10.1111/j.1440-1746.1995.tb01096.x
Paré, 1983, Serum-ascites albumin concentration gradient: a physiologic approach to the differential diagnosis of ascites, Gastroenterology, 85, 240, 10.1016/0016-5085(83)90306-2
Mauer, 1988, Usefulness of serum-ascites albumin difference in separating transudative from exudative ascites. another look, Dig Dis Sci, 33, 1208, 10.1007/BF01536667
Wong, 2008, Does this patient have bacterial peritonitis or portal hypertension? How do I perform a paracentesis and analyze the results?, JAMA, 299, 1166, 10.1001/jama.299.10.1166
Farias, 2014, Serum B-type natriuretic peptide in the initial workup of patients with new onset ascites: a diagnostic accuracy study, Hepatology, 59, 1043, 10.1002/hep.26643
Liu, 2014, Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites, Ann Hepatol, 13, 357, 10.1016/S1665-2681(19)30865-8
Cascinu, 1997, Tumor markers in the diagnosis of malignant serous effusions, Am J Clin Oncol, 20, 247, 10.1097/00000421-199706000-00007
Collazos, 1992, CA 125 serum levels in patients with non-neoplastic liver diseases. A clinical and laboratory study, Scand J Clin Lab Invest, 52, 201, 10.3109/00365519209088786
Shakil, 1996, Diagnostic features of tuberculous peritonitis in the absence and presence of chronic liver disease: a case control study, Am J Med, 100, 179, 10.1016/S0002-9343(97)89456-9
Shen, 2013, Diagnostic accuracy of adenosine deaminase for tuberculous peritonitis: a meta-analysis, Arch Med Sci, 9, 601, 10.5114/aoms.2013.36904
Kang, 2012, Role of ascites adenosine deaminase in differentiating between tuberculous peritonitis and peritoneal carcinomatosis, World J Gastroenterol, 18, 2837, 10.3748/wjg.v18.i22.2837
He, 2019, Percutaneous drainage versus peritoneal lavage for pancreatic ascites in severe acute pancreatitis: a prospective randomized trial, Pancreas, 48, 343, 10.1097/MPA.0000000000001251
Evans, 2003, Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites, Hepatology, 37, 897, 10.1053/jhep.2003.50119
Fernández, 2019, Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe, J Hepatol, 70, 398, 10.1016/j.jhep.2018.10.027
Piano, 2016, The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial, Hepatology, 63, 1299, 10.1002/hep.27941
Kim, 2014, Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis, Am J Gastroenterol, 109, 1436, 10.1038/ajg.2014.212
Lim, 2015, Long-term outcomes after hospitalization with spontaneous bacterial peritonitis, J Dig Dis, 16, 228, 10.1111/1751-2980.12228
Rimola, 2000, Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club, J Hepatol, 32, 142, 10.1016/S0168-8278(00)80201-9
van de Geijn, 2016, A new flow cytometric method for differential cell counting in ascitic fluid, Cytometry B Clin Cytom, 90, 506, 10.1002/cyto.b.21171
Fleming, 2014, UF-1000I: validation of the body fluid mode for counting cells in body fluids, Clin Chem Lab Med, 52, 1781, 10.1515/cclm-2014-0512
Nousbaum, 2007, Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis, Hepatology, 45, 1275, 10.1002/hep.21588
Terg, 1992, Analysis of clinical course and prognosis of culture-positive spontaneous bacterial peritonitis and neutrocytic ascites. Evidence of the same disease, Dig Dis Sci, 37, 1499, 10.1007/BF01296493
Enomoto, 2018, Amplification of bacterial genomic DNA from all ascitic fluids with a highly sensitive polymerase chain reaction, Mol Med Rep, 18, 2117
Gravito-Soares, 2017, Spontaneous fungal peritonitis: a rare but severe complication of liver cirrhosis, Eur J Gastroenterol Hepatol, 29, 1010, 10.1097/MEG.0000000000000927
Bajaj, 2018, Prediction of fungal infection development and their impact on survival using the NACSELD cohort, Am J Gastroenterol, 113, 556, 10.1038/ajg.2017.471
Soriano, 2010, Secondary bacterial peritonitis in cirrhosis: a retrospective study of clinical and analytical characteristics, diagnosis and management, J Hepatol, 52, 39, 10.1016/j.jhep.2009.10.012
Runyon, 2004, Management of adult patients with ascites due to cirrhosis, Hepatology, 39, 841, 10.1002/hep.20066
Runyon, 1991, Ascitic fluid and serum cefotaxime and desacetyl cefotaxime levels in patients treated for bacterial peritonitis, Dig Dis Sci, 36, 1782, 10.1007/BF01296625
Piano, 2019, Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide, Gastroenterology, 156, 1368, 10.1053/j.gastro.2018.12.005
Horan, 2008, CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting, Am J Infect Control, 36, 309, 10.1016/j.ajic.2008.03.002
2018, EASL clinical practice guidelines for the management of patients with decompensated cirrhosis, J Hepatol, 69, 406, 10.1016/j.jhep.2018.03.024
Fernández, 2016, The challenges of multi-drug-resistance in hepatology, J Hepatol, 65, 1043, 10.1016/j.jhep.2016.08.006
Fong, 1989, Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis, Hepatology, 9, 423, 10.1002/hep.1840090313
Fernández, 2016, Antibiotic prophylaxis in cirrhosis: good and bad, Hepatology, 63, 2019, 10.1002/hep.28330
Chavez-Tapia, 2011, Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review, Aliment Pharmacol Ther, 34, 509, 10.1111/j.1365-2036.2011.04746.x
Cohen, 2009, Antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleeding, Cochrane Database Syst Rev, CD004791
Tripathi, 2015, U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients, Gut, 64, 1680, 10.1136/gutjnl-2015-309262
Harrison, 2016, Assessment and management of cirrhosis in people older than 16 years: summary of NICE guidance, BMJ, 354
Grangé, 1998, Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial, J Hepatol, 29, 430, 10.1016/S0168-8278(98)80061-5
Rolachon, 1995, Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial, Hepatology, 22, 1171
Soriano, 1991, Selective intestinal decontamination prevents spontaneous bacterial peritonitis, Gastroenterology, 100, 477, 10.1016/0016-5085(91)90219-B
Terg, 2008, Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study, J Hepatol, 48, 774, 10.1016/j.jhep.2008.01.024
Téllez-Ávila, 2013, Primary prophylaxis with ciprofloxacin in cirrhotic patients with ascites: a randomized, double blind study, Ann Hepatol, 13, 65, 10.1016/S1665-2681(19)30906-8
Fernández, 2007, Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis, Gastroenterology, 133, 818, 10.1053/j.gastro.2007.06.065
Runyon, 2013, Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012, Hepatology, 57, 1651, 10.1002/hep.26359
Moreau, 2018, Effects of long-term norfloxacin therapy in patients with advanced cirrhosis, Gastroenterology, 155, 1816, 10.1053/j.gastro.2018.08.026
Terg, 2015, Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study, J Hepatol, 62, 1056, 10.1016/j.jhep.2014.11.036
Bruns, 2015, Low ascitic fluid protein does not indicate an increased risk for spontaneous bacterial peritonitis in current cohorts, J Hepatol, 63, 527, 10.1016/j.jhep.2015.03.040
Titó, 1988, Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors, Hepatology, 8, 27, 10.1002/hep.1840080107
Altman, 1995, Survival after a first episode of spontaneous bacterial peritonitis. prognosis of potential candidates for orthotopic liver transplantation, J Gastroenterol Hepatol, 10, 47, 10.1111/j.1440-1746.1995.tb01046.x
Ginés, 1990, Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial, Hepatology, 12, 716, 10.1002/hep.1840120416
Goel, 2017, Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis, Aliment Pharmacol Ther, 46, 1029, 10.1111/apt.14361
Min, 2014, Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study, Aliment Pharmacol Ther, 40, 695, 10.1111/apt.12875
Dam, 2016, Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites, Hepatology, 64, 1265, 10.1002/hep.28737
Reynolds, 1978, Advantages of treatment of ascites without sodium restriction and without complete removal of excess fluid, Gut, 19, 549, 10.1136/gut.19.6.549
Descos, 1983, Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial, Hepatogastroenterology, 30, 15
Gauthier, 1986, Salt or no salt in the treatment of cirrhotic ascites: a randomised study, Gut, 27, 705, 10.1136/gut.27.6.705
Bernardi, 1993, Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content, Liver, 13, 156, 10.1111/j.1600-0676.1993.tb00624.x
Soulsby, 1997, The effect of dietary sodium restriction on energy and protein intake in patients with cirrhosis, Hepatology, 26, 1013
Gu, 2012, Effect of a diet with unrestricted sodium on ascites in patients with hepatic cirrhosis, Gut Liver, 6, 355, 10.5009/gnl.2012.6.3.355
Sorrentino, 2012, Preservation of nutritional-status in patients with refractory ascites due to hepatic cirrhosis who are undergoing repeated paracentesis, J Gastroenterol Hepatol, 27, 813, 10.1111/j.1440-1746.2011.07043.x
Morando, 2015, Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study, Liver Int, 35, 1508, 10.1111/liv.12583
Powles, 2013, Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 H urinary sodium excretion and dietary surveys worldwide, BMJ Open, 3, 10.1136/bmjopen-2013-003733
Gonçalves, 2016, Sodium and potassium urinary excretion and dietary intake: a cross-sectional analysis in adolescents, Food Nutr Res, 60, 29442, 10.3402/fnr.v60.29442
Haberl, 2018, To salt or not to salt?-That is the question in cirrhosis, Liver Int, 38, 1148, 10.1111/liv.13750
Walbaum, 2016, Sodium restriction in patients with cirrhotic ascites: a protocol for a systematic review, Syst Rev, 5, 10.1186/s13643-016-0250-4
Bernardi, 1994, Hepatorenal disorders: role of the renin-angiotensin-aldosterone system, Semin Liver Dis, 14, 23, 10.1055/s-2007-1007295
Bernardi, 1985, Importance of plasma aldosterone concentration on the natriuretic effect of spironolactone in patients with liver cirrhosis and ascites, Digestion, 31, 189, 10.1159/000199198
Brater, 2011, Update in diuretic therapy: clinical pharmacology, Semin Nephrol, 31, 483, 10.1016/j.semnephrol.2011.09.003
Pérez-Ayuso, 1983, Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system, Gastroenterology, 84, 961, 10.1016/0016-5085(83)90198-1
Fogel, 1981, Diuresis in the ascitic patient: a randomized controlled trial of three regimens, J Clin Gastroenterol, 3(Suppl 1), 73, 10.1097/00004836-198100031-00016
Overdiek, 1985, New insights into the pharmacokinetics of spironolactone, Clin Pharmacol Ther, 38, 469, 10.1038/clpt.1985.206
Shear, 1970, Compartmentalization of ascites and edema in patients with hepatic cirrhosis, N Engl J Med, 282, 1391, 10.1056/NEJM197006182822502
Angeli, 1994, Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites, Hepatology, 19, 72, 10.1002/hep.1840190113
Sarin, 1988, Bumetanide, spironolactone and a combination of the two, in the treatment of ascites due to liver disease. A prospective, controlled, randomized trial, Digestion, 41, 101, 10.1159/000199738
Laffi, 1991, Comparison of the effects of torasemide and furosemide in nonazotemic cirrhotic patients with ascites: a randomized, double-blind study, Hepatology, 13, 1101, 10.1002/hep.1840130616
Gerbes, 1993, Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. A randomized, double blind cross-over trial, J Hepatol, 17, 353, 10.1016/S0168-8278(05)80217-X
Santos, 2003, Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety, J Hepatol, 39, 187, 10.1016/S0168-8278(03)00188-0
Angeli, 2010, Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial, Gut, 59, 98, 10.1136/gut.2008.176495
Gatta, 1991, A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients, Hepatology, 14, 231, 10.1002/hep.1840140205
Angeli, 1990, Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance, Eur J Clin Invest, 20, 111, 10.1111/j.1365-2362.1990.tb01800.x
Pockros, 1986, Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema, Gastroenterology, 90, 1827, 10.1016/0016-5085(86)90249-0
Stanley, 1989, Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites, N Engl J Med Overseas Ed, 321, 1632, 10.1056/NEJM198912143212403
Sherlock, 1966, Complications of diuretic therapy in hepatic cirrhosis, Lancet, 1, 1049, 10.1016/S0140-6736(66)91005-1
Bellati, 1986, Gynaecomastia after spironolactone and potassium canrenoate, Lancet, 1
Mimidis, 2007, Eplerenone relieves spironolactone-induced painful gynaecomastia in patients with decompensated hepatitis B-related cirrhosis, Scand J Gastroenterol, 42, 1516, 10.1080/00365520701676070
Dimitriadis, 2011, Eplerenone reverses spironolactone-induced painful gynaecomastia in cirrhotics, Hepatol Int, 5, 738, 10.1007/s12072-010-9235-x
Murata, 2019, Overlooked muscle cramps in patients with chronic liver disease: in relation to the prevalence of muscle cramps, Eur J Gastroenterol Hepatol, 31, 375, 10.1097/MEG.0000000000001294
Peng, 2019, Symptom prevalence and quality of life of patients with end-stage liver disease: a systematic review and meta-analysis, Palliat Med, 33, 24, 10.1177/0269216318807051
Vidot, 2014, Systematic review: the treatment of muscle cramps in patients with cirrhosis, Aliment Pharmacol Ther, 40, 221, 10.1111/apt.12827
Abd-Elsalam, 2019, Randomized-controlled trial of methocarbamol as a novel treatment for muscle cramps in cirrhotic patients, Eur J Gastroenterol Hepatol, 31, 499, 10.1097/MEG.0000000000001310
Vidot, 2018, Randomised clinical trial: oral taurine supplementation versus placebo reduces muscle cramps in patients with chronic liver disease, Aliment Pharmacol Ther, 48, 704, 10.1111/apt.14950
Elfert, 2016, Randomized placebo-controlled study of baclofen in the treatment of muscle cramps in patients with liver cirrhosis, Eur J Gastroenterol Hepatol, 28, 1280, 10.1097/MEG.0000000000000714
Eisenmenger, 1950, Electrolyte studies on patients with cirrhosis of the liver, J Clin Invest, 29, 1491, 10.1172/JCI102390
El-Bokl, 2009, Spot urinary sodium for assessing dietary sodium restriction in cirrhotic ascites, World J Gastroenterol, 15, 3631, 10.3748/wjg.15.3631
Mohii, 2013, Diagnostic usefulness of the random urine Na/K ratio in predicting therapeutic response for diuretics in cirrhotic patients with ascites, J Egypt Soc Parasitol, 43, 767, 10.12816/0006433
Spasovski, 2014, Clinical practice guideline on diagnosis and treatment of hyponatraemia, Intensive Care Med, 40, 320, 10.1007/s00134-014-3210-2
Angeli, 2006, Hyponatremia in cirrhosis: results of a patient population survey, Hepatology, 44, 1535, 10.1002/hep.21412
Sersté, 2012, Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites, J Hepatol, 57, 274, 10.1016/j.jhep.2012.03.018
Kim, 2008, Hyponatremia and mortality among patients on the liver-transplant waiting list, N Engl J Med, 359, 1018, 10.1056/NEJMoa0801209
Biggins, 2006, Evidence-based incorporation of serum sodium concentration into MELD, Gastroenterology, 130, 1652, 10.1053/j.gastro.2006.02.010
McCormick, 1990, Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites, Gut, 31, 204, 10.1136/gut.31.2.204
Jalan R , Mookerjee R , Cheshire L , et al . Albumin [232] infusion for severe hyponatraemia in patients with refractory ascites: a randomized clinical trial. J Hepatol 2007;46:S95. doi:10.1016/S0168-8278(07)61830-3
Ginès, 1988, Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis, Gastroenterology, 94, 1493, 10.1016/0016-5085(88)90691-9
García-Compeán, 1993, Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial, Liver, 13, 233, 10.1111/j.1600-0676.1993.tb00637.x
Luca, 1995, Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis, Hepatology, 22, 753
Bajaj, 2018, The impact of albumin use on resolution of hyponatremia in hospitalized patients with cirrhosis, Am J Gastroenterol, 113, 1339, 10.1038/s41395-018-0119-3
Bernardi, 2012, Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials, Hepatology, 55, 1172, 10.1002/hep.24786
Kütting, 2017, Insufficient evidence of benefit regarding mortality due to albumin substitution in HCC-free cirrhotic patients undergoing large volume paracentesis, J Gastroenterol Hepatol, 32, 327, 10.1111/jgh.13421
Bernardi, 2015, Hyponatremia in patients with cirrhosis of the liver, J Clin Med, 4, 85, 10.3390/jcm4010085
Bichet, 1982, Role of vasopressin in abnormal water excretion in cirrhotic patients, Ann Intern Med, 96, 413, 10.7326/0003-4819-96-4-413
Eisenmenger, 1949, The effect of rigid sodium restriction in patients with cirrhosis of the liver and ascites, J Lab Clin Med, 34, 1029
Moore, 2006, Guidelines on the management of ascites in cirrhosis, Gut, 55, vi1, 10.1136/gut.2006.099580
Vizzini, 2011, Changing picture of central nervous system complications in liver transplant recipients, Liver Transpl, 17, 1279, 10.1002/lt.22383
Verbalis, 2013, Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations, Am J Med, 126, S1, 10.1016/j.amjmed.2013.07.006
Hoorn, 2017, Diagnosis and treatment of hyponatremia: compilation of the guidelines, J Am Soc Nephrol, 28, 1340, 10.1681/ASN.2016101139
Wong, 2012, Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity, Gut, 61, 108, 10.1136/gutjnl-2011-300157
Dahl, 2012, Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia, Aliment Pharmacol Ther, 36, 619, 10.1111/apt.12025
Yan, 2015, The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials, BMC Gastroenterol, 15, 10.1186/s12876-015-0297-z
Llach, 1988, Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites, Gastroenterology, 94, 482, 10.1016/0016-5085(88)90441-6
Kalambokis, 2007, Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites, J Hepatol, 46, 213, 10.1016/j.jhep.2006.09.012
Singh, 2012, Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study, J Hepatol, 56, 348, 10.1016/j.jhep.2011.04.027
Ali, 2014, Clinical study on the therapeutic role of midodrine in non azotemic cirrhotic patients with tense ascites: a double-blind, placebo-controlled, randomized trial, Hepatogastroenterology, 61, 1915
Salerno, 1993, Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients, Am J Gastroenterol, 88, 514
Grabau, 2004, Performance standards for therapeutic abdominal paracentesis, Hepatology, 40, 484, 10.1002/hep.20317
Chivinge, 2015, Implementing a nurse-led paracentesis service to improve patient care and experience in a day case unit, Gastrointestinal Nursing, 13, S11, 10.12968/gasn.2015.13.Sup10.S11
Sakai, 2005, Choosing the location for non-image guided abdominal paracentesis, Liver Int, 25, 984, 10.1111/j.1478-3231.2005.01149.x
Hurd, 1994, The location of abdominal wall blood vessels in relationship to abdominal landmarks apparent at laparoscopy, Am J Obstet Gynecol, 171, 642, 10.1016/0002-9378(94)90076-0
Saber, 2004, Safety zones for anterior abdominal wall entry during laparoscopy: a CT scan mapping of epigastric vessels, Ann Surg, 239, 182, 10.1097/01.sla.0000109151.53296.07
Joy, 2017, Clinical anatomy of the inferior epigastric artery with special relevance to invasive procedures of the anterior abdominal wall, J Minim Access Surg, 13, 18, 10.4103/0972-9941.181331
Rowley, 2018, Ultrasound imaging guidance and large volume paracentesis: an analysis of safety, cost-effectiveness, and utility in restricting unnecessary transfusion, Hepatology, 68, 568a
Pache, 2005, Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease, Aliment Pharmacol Ther, 21, 525, 10.1111/j.1365-2036.2005.02387.x
Hung, 2018, Acute kidney injury, but not sepsis, is associated with higher procedure-related bleeding in patients with decompensated cirrhosis, Liver Int, 38, 1437, 10.1111/liv.13712
Lin, 2015, Hemorrhagic complications following abdominal paracentesis in acute on chronic liver failure: a propensity score analysis, Medicine, 94, 10.1097/MD.0000000000002225
Patel, 2012, Evaluation of hospital complications and costs associated with using ultrasound guidance during abdominal paracentesis procedures, J Med Econ, 15, 1, 10.3111/13696998.2011.628723
Peltekian, 1997, Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites, Am J Gastroenterol, 92, 394
Arora, 2019, Paracentesis-Induced circulatory dysfunction with modest-volume paracentesis is partly ameliorated by albumin infusion in acute-on-chronic liver failure, Hepatology
Abdel-Khalek, 2010, Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis, Arab Journal of Gastroenterology, 11, 24, 10.1016/j.ajg.2010.01.006
Altman, 1998, Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis, Eur J Gastroenterol Hepatol, 10, 5, 10.1097/00042737-199801000-00002
Bertrán, 1991, [Impact on the energetic-proteic nutritional status of total paracentesis combined with infusion of albumin or dextran-70 in the therapy of tension ascites in liver cirrhosis], Rev Esp Enferm Dig, 79, 320
Fassio, 1992, Paracentesis with dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study, J Hepatol, 14, 310, 10.1016/0168-8278(92)90176-P
García-Compean, 2002, Treatment of cirrhotic tense ascites with dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial, Ann Hepatol, 1, 29, 10.1016/S1665-2681(19)32189-1
Pérez, 1995, Paracentesis Masiva Con Reposician de dextran 70 vs Albumina en Pacientes cirrhotics Con ascites a tension, Rev Gastro Max, 60, 22
Moreau, 2006, Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial, Liver Int, 26, 46, 10.1111/j.1478-3231.2005.01188.x
Planas, 1990, Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study, Gastroenterology, 99, 1736, 10.1016/0016-5085(90)90481-F
Salerno, 1991, Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites, Hepatology, 13, 707, 10.1002/hep.1840130416
Sola-Vera, 2003, Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites, Hepatology, 37, 1147, 10.1053/jhep.2003.50169
Zhao, 2000, Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis, Chin Med J, 113, 27
Alessandria, 2011, Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study, Dig Liver Dis, 43, 881
Alsebaey A , Bassuni A , Khalil M , et al . Absno: 2296. Low-dose albumin is equally effective as standard dose albumin in preventing PICD following large volume paracentesis (LVP). Hepatol Int 2013:2296.
Johnson, 2015, Reduced albumin dosing during large-volume paracentesis is not associated with adverse clinical outcomes, Dig Dis Sci, 60, 2190, 10.1007/s10620-015-3578-z
Mirici-Cappa, 2011, How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure, World J Gastroenterol, 17, 3479, 10.3748/wjg.v17.i30.3479
Mandorfer, 2014, Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis, Gastroenterology, 146, 1680, 10.1053/j.gastro.2014.03.005
Sort, 1999, Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis, N Engl J Med, 341, 403, 10.1056/NEJM199908053410603
XUE, 2002, Effect of albumin infusion on preventing the deterioration of renal function in patients with spontaneous bacterial peritonitis, Chin J Dig Dis, 3, 32, 10.1046/j.1443-9573.2002.00062.x
Chen, 2009, Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis, Scand J Gastroenterol, 44, 619, 10.1080/00365520902719273
Fernández, 2005, A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis, Hepatology, 42, 627, 10.1002/hep.20829
de Araujo, 2012, Low-dose albumin in the treatment of spontaneous bacterial peritonitis: should we change the standard treatment?, Gut, 61, 1371, 10.1136/gutjnl-2011-301739
Weisberg IS , Sharaiha RZ , Goldberg DS , et al . S1848 a kidney function determined treatment algorithm for administration of albumin in the management of spontaneous bacterial peritonitis (SBP). Gastroenterology 2009;136:A-829. doi:10.1016/S0016-5085(09)63821-X
Afinogenova, 2015, The efficacy and safety profile of albumin administration for patients with cirrhosis at high risk of hepatorenal syndrome is dose dependent, Gastroenterol Rep, 3, 216, 10.1093/gastro/gov032
Thévenot, 2015, Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial, J Hepatol, 62, 822, 10.1016/j.jhep.2014.11.017
Fernandez, 2018, Albumin administration in the prevention of hepatorenal syndrome (HRS) and death in patients with advanced cirrhosis and non-SBP infections, J Hepatol, 68, S253
Solà, 2018, Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial, J Hepatol, 69, 1250, 10.1016/j.jhep.2018.08.006
Gentilini, 1999, Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial, J Hepatol, 30, 639, 10.1016/S0168-8278(99)80194-9
Vizzutti F et al . Diuretic and natriuretic effects of long-term albumin infusion in patients with cirrhosis and ascites: a randomised controlled study. J Hepatol 2001;34:17. doi:10.1016/S0168-8278(01)80051-9
Romanelli, 2006, Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial, World J Gastroenterol, 12, 1403, 10.3748/wjg.v12.i9.1403
Di Pascoli, 2019, Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites, Liver Int, 39, 98, 10.1111/liv.13968
Wong, 1995, Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites, Ann Intern Med, 122, 816, 10.7326/0003-4819-122-11-199506010-00002
Wong, 1997, The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt, Gastroenterology, 112, 899, 10.1053/gast.1997.v112.pm9041252
Quiroga, 1995, Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters, Hepatology, 21, 986
Lebrec, 1996, Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French group of clinicians and a group of biologists, J Hepatol, 25, 135, 10.1016/S0168-8278(96)80065-1
Wong, 1999, Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites, Am J Med, 106, 315, 10.1016/S0002-9343(99)00029-7
Gerbes, 1998, Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites, Hepatology, 28, 683, 10.1002/hep.510280313
Rössle, 2000, A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites, N Engl J Med, 342, 1701, 10.1056/NEJM200006083422303
Ginès, 2002, Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis, Gastroenterology, 123, 1839, 10.1053/gast.2002.37073
Sanyal, 2003, The North American study for the treatment of refractory ascites, Gastroenterology, 124, 634, 10.1053/gast.2003.50088
Salerno, 2004, Randomized controlled study of tips versus paracentesis plus albumin in cirrhosis with severe ascites, Hepatology, 40, 629, 10.1002/hep.20364
Narahara, 2011, Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial, J Gastroenterol, 46, 78, 10.1007/s00535-010-0282-9
Bureau, 2017, Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites, Gastroenterology, 152, 157, 10.1053/j.gastro.2016.09.016
Geeroms, 2017, Expanded polytetrafluoroethylene-covered stent-grafts for transjugular intrahepatic portosystemic shunts in cirrhotic patients: long-term patency and clinical outcome results, Eur Radiol, 27, 1795, 10.1007/s00330-016-4570-5
Perarnau, 2014, Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial, J Hepatol, 60, 962, 10.1016/j.jhep.2014.01.015
Bai, 2014, Tips improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis, World J Gastroenterol, 20, 2704, 10.3748/wjg.v20.i10.2704
Chen, 2014, Prophylactic use of transjugular intrahepatic portosystemic shunt AIDS in the treatment of refractory ascites: metaregression and trial sequential meta-analysis, J Clin Gastroenterol, 48, 290, 10.1097/MCG.0b013e3182a115e9
Campbell, 2005, Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy, Hepatology, 42, 635, 10.1002/hep.20840
Gülberg, 2002, Improved quality of life in patients with refractory or recidivant ascites after insertion of transjugular intrahepatic portosystemic shunts, Digestion, 66, 127, 10.1159/000065593
Allard, 2001, Effects of ascites resolution after successful tips on nutrition in cirrhotic patients with refractory ascites, Am J Gastroenterol, 96, 2442, 10.1111/j.1572-0241.2001.04051.x
Riggio, 2010, Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial, J Hepatol, 52, S82, 10.1016/S0168-8278(10)60193-6
Wang, 2017, Eight millimetre covered tips does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding, J Hepatol, 67, 508, 10.1016/j.jhep.2017.05.006
Mollaiyan, 2017, The underdilation of nitinol stents at tips implantation: solution or illusion?, Eur J Radiol, 89, 123, 10.1016/j.ejrad.2017.01.032
Miraglia, 2017, Transjugular intrahepatic portosystemic shunts in patients with cirrhosis with refractory ascites: comparison of clinical outcomes by using 8- and 10-mm PTFE-covered stents, Radiology, 284, 281, 10.1148/radiol.2017161644
Sarwar, 2018, Hospital volume and mortality after transjugular intrahepatic portosystemic shunt creation in the United States, Hepatology, 67, 690, 10.1002/hep.29354
Jalan, 1995, Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage, J Hepatol, 23, 123, 10.1016/0168-8278(95)80325-4
Berlioux, 2014, Pre-transjugular intrahepatic portosystemic shunts (tips) prediction of post-TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests, Hepatology, 59, 622, 10.1002/hep.26684
Masson, 2008, Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience, QJM, 101, 493, 10.1093/qjmed/hcn037
Malinchoc, 2000, A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts, Hepatology, 31, 864, 10.1053/he.2000.5852
Al Sibae, 2011, Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or tips, Dig Dis Sci, 56, 977, 10.1007/s10620-010-1390-3
Bercu, 2015, Tips for refractory ascites: a 6-year single-center experience with expanded polytetrafluoroethylene-covered stent-grafts, AJR Am J Roentgenol, 204, 654, 10.2214/AJR.14.12885
Bureau, 2011, Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by tips, J Hepatol, 54, 901, 10.1016/j.jhep.2010.08.025
Salerno, 2007, Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data, Gastroenterology, 133, 825, 10.1053/j.gastro.2007.06.020
Hamel, 2014, Prognostic factors in patients with refractory ascites treated by transjugular intrahepatic porto-systemic shunt: from the liver to the kidney, Dig Liver Dis, 46, 1001, 10.1016/j.dld.2014.06.013
Nardelli, 2017, Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement, Clin Gastroenterol Hepatol, 15, 934, 10.1016/j.cgh.2016.10.028
Benmassaoud A , Roccarina D , Yu D , et al . SAT-016-Impact of sarcopenia in patients undergoing transjugular intrahepatic portosystemic shunt insertion for refractory ascites. J Hepatol 2019;70:e632. doi:10.1016/S0618-8278(19)31259-9
Tan, 2015, Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion, J Gastroenterol Hepatol, 30, 389, 10.1111/jgh.12725
Parvinian, 2014, Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites, Diagn Interv Radiol, 20, 58
Grunwald, 2016, A standardized assessment of functional disability predicts 1-year mortality in patients undergoing transjugular intrahepatic portosystemic shunt for refractory ascites, J Clin Gastroenterol, 50, 75, 10.1097/MCG.0000000000000339
Bhangui, 2012, Assessment of risk for non-hepatic surgery in cirrhotic patients, J Hepatol, 57, 874, 10.1016/j.jhep.2012.03.037
Lemmer, 1983, Management of spontaneous umbilical hernia disruption in the cirrhotic patient, Ann Surg, 198, 30, 10.1097/00000658-198307000-00006
Salamone, 2018, The abdominal wall hernia in cirrhotic patients: a historical challenge, World J Emerg Surg, 13, 35, 10.1186/s13017-018-0196-z
Elshoura, 2019, Surgical repair of umbilical hernia in cirrhotic patients with ascites: is it safe?, Egypt J Surg, 38, 52, 10.4103/ejs.ejs_110_18
Coelho, 2016, Umbilical hernia in patients with liver cirrhosis: a surgical challenge, World J Gastrointest Surg, 8, 476, 10.4240/wjgs.v8.i7.476
Krowka, 2013, Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward, J Hepatol, 59, 367, 10.1016/j.jhep.2013.03.026
Orman, 2009, Outcomes of patients with chest tube insertion for hepatic hydrothorax, Hepatol Int, 3, 582, 10.1007/s12072-009-9136-z
Ditah, 2015, Transjugular intrahepatic portosystemic stent shunt for medically refractory hepatic hydrothorax: a systematic review and cumulative meta-analysis, World J Hepatol, 7, 1797, 10.4254/wjh.v7.i13.1797
Dhanasekaran, 2010, Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis, Am J Gastroenterol, 105, 635, 10.1038/ajg.2009.634
Albillos, 2017, Stratifying risk in the prevention of recurrent variceal hemorrhage: results of an individual patient meta-analysis, Hepatology, 66, 1219, 10.1002/hep.29267
Villanueva, 2019, β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, 393, 1597, 10.1016/S0140-6736(18)31875-0
Turco, 2020, Lowering portal pressure improves outcomes of patients with cirrhosis, with or without ascites: a meta-analysis, Clin Gastroenterol Hepatol, 18, 313, 10.1016/j.cgh.2019.05.050
Pérez-Paramo, 2000, Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites, Hepatology, 31, 43, 10.1002/hep.510310109
Reiberger, 2013, Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis, J Hepatol, 58, 911, 10.1016/j.jhep.2012.12.011
Krag, 2012, The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease, Gut, 61, 967, 10.1136/gutjnl-2011-301348
Sersté, 2010, Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites, Hepatology, 52, 1017, 10.1002/hep.23775
Bossen, 2016, Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: post hoc analysis of three randomized controlled trials with 1198 patients, Hepatology, 63, 1968, 10.1002/hep.28352
Chirapongsathorn, 2016, Nonselective β-blockers and survival in patients with cirrhosis and ascites: a systematic review and meta-analysis, Clin Gastroenterol Hepatol, 14, 1096, 10.1016/j.cgh.2016.01.012
Sinha, 2017, Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites, J Hepatol, 67, 40, 10.1016/j.jhep.2017.02.005
Facciorusso, 2018, Nonselective beta-blockers do not affect survival in cirrhotic patients with ascites, Dig Dis Sci, 63, 1737, 10.1007/s10620-018-5092-6
Wong, 2019, Assessing the safety of beta-blocker therapy in cirrhosis patients with ascites: a meta-analysis, Liver Int, 39, 1080, 10.1111/liv.14040
Njei, 2016, Beta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters, Gut, 65, 1393, 10.1136/gutjnl-2016-312129
Bellot, 2013, Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study, J Hepatol, 58, 922, 10.1016/j.jhep.2012.12.020
Stirnimann, 2017, Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis, Aliment Pharmacol Ther, 46, 981, 10.1111/apt.14331
Bureau, 2017, Alfapump® system vs. large volume paracentesis for refractory ascites: a multicenter randomized controlled study, J Hepatol, 67, 940, 10.1016/j.jhep.2017.06.010
Lepida, 2019, Systematic review with meta-analysis: automated low-flow ascites pump therapy for refractory ascites, Aliment Pharmacol Ther, 50, 978, 10.1111/apt.15502
NICE . Subcutaneous automated low-flow pump implantation for refractory ascites caused by cirrhosis, 2018. https://www.nice.org.uk/guidance/IPG631/chapter/1-Recommendations
Salerno, 2007, Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis, Gut, 56, 1310
Trebicka, 2019, Addressing profiles of systemic inflammation across the different clinical phenotypes of acutely decompensated cirrhosis, Front Immunol, 10, 10.3389/fimmu.2019.00476
Israelsen M , Krag A , Allegretti AS , et al . Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev 2017;44:CD011532. doi:10.1002/14651858.CD011532.pub2
Allegretti AS , Israelsen M , Krag A , et al . Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. Cochrane Database Syst Rev 2017;4:CD011532. doi:10.1002/14651858.CD005162.pub4
Palaniyappan, 2020, Editorial: treating hepatorenal syndrome-a window and the views, Aliment Pharmacol Ther, 52, 895, 10.1111/apt.15943
Boyer, 2011, Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics, J Hepatol, 55, 315, 10.1016/j.jhep.2010.11.020
Galla, 2000, Clinical practice guideline on shared decision-making in the appropriate initiation of and withdrawal from dialysis. The Renal Physicians Association and the American Society of Nephrology, J Am Soc Nephrol, 11, 1340, 10.1681/ASN.V1171340
Day, 2015, Patient experience of non-malignant ascites and its treatment: a qualitative study, Int J Palliat Nurs, 21, 372, 10.12968/ijpn.2015.21.8.372
Macdonald, 2019, Quality of life measures predict mortality in patients with cirrhosis and severe ascites, Aliment Pharmacol Ther, 49, 321, 10.1111/apt.15084
Mazzarelli, 2018, Palliative care in end-stage liver disease: time to do better?, Liver Transpl, 24, 961, 10.1002/lt.25193
Rakoski, 2019, Palliative care and end-stage liver disease: a critical review of current knowledge, Curr Opin Gastroenterol, 35, 155, 10.1097/MOG.0000000000000530
Hudson, 2018, Cirrhosis with ascites in the last year of life: a nationwide analysis of factors shaping costs, health-care use, and place of death in England, Lancet Gastroenterol Hepatol, 3, 95, 10.1016/S2468-1253(17)30362-X
Fleming, 2009, Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review, J Pain Symptom Manage, 38, 341, 10.1016/j.jpainsymman.2008.09.008
White, 2012, PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites: a NICE medical technology guidance, Appl Health Econ Health Policy, 10, 299, 10.1007/BF03261864
Stukan, 2017, Drainage of malignant ascites: patient selection and perspectives, Cancer Manag Res, 9, 115, 10.2147/CMAR.S100210
Macken, 2019, Permanent indwelling peritoneal catheters for palliation of refractory ascites in end-stage liver disease: a systematic review, Liver Int, 39, 1594, 10.1111/liv.14162
Macken, 2020, Randomised clinical trial: palliative long-term abdominal drains vs large-volume paracentesis in refractory ascites due to cirrhosis, Aliment Pharmacol Ther, 52, 107, 10.1111/apt.15802
Schmidt, 2015, Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010, Gastroenterology, 148, 967, 10.1053/j.gastro.2015.01.032
de Castro, 1991, Myxedema ascites. Report of two cases and review of the literature, J Clin Gastroenterol, 13, 411, 10.1097/00004836-199108000-00010